Company Overview and News
The housing market has perked up with the start of summer thanks to soaring demand for homes. This is especially true as new home sales jumped to the highest level in May since November 2017. Sales of new homes in the United States rose 6.7% to a seasonally adjusted annual rate of 689,000 in May. The robust growth was driven by an inventory crunch for previously owned houses. The median sales price in May was 3.
Though homebuilders are struggling with higher lumber prices as well as labor and land shortages, an upbeat housing starts report was a silver lining in the space. U.S. housing starts climbed 5% in May to a seasonally adjusted annual rate of 1.35 million homes, representing the highest level since July 2007. The uptick in construction activity was driven by acceleration in both single-family and multi-family home construction that rose 3.
A smart beta exchange traded fund, the PowerShares Dynamic Building & Construction Portfolio (PKB - Free Report) debuted on 10/26/2005, and offers broad exposure to the Industrials ETFs category of the U.S. equity market.
XHB TSCO PHM ITB AKAM
Recently released existing and new U.S. home sales data for the month of March deserve a big round of applause. Despite persistently low inventories and a shoot-up in price, both rose and beat market expectations.
XHB SQ SQNXF UTX ITB
The PowerShares Dynamic Building & Construction Portfolio (PKB - Free Report) made its debut on 10/26/2005, and is a smart beta exchange traded fund that provides broad exposure to the Industrials ETFs category of the U.S. equity market.
XHB PHM LEN LEN.B ITB
Designed to provide broad exposure to the Industrials - Engineering and Construction segment of the U.S. equity market, the PowerShares Dynamic Building & Construction Portfolio (PKB - Free Report) is a passively managed exchange traded fund launched on 10/26/2005.
XHB FXD UNP AAON PHM LEN FUTY LEN.B ITB
The Q1 earnings season has kicked off with a few major banks set to report this week. Earnings for the S&P 500 index are expected to grow 16% from the same period last year on 7.4% higher revenues. Earnings growth is much higher than the Q4 growth of 13.5% and represents the highest quarterly earnings growth in seven years (read: 5 Ultra-Cheap Growth ETFs for a Large-Cap Play This Spring). Additionally, the revision trend has been impressive with earnings estimates moving up from 10.
LPX LPCCW TKR VIS CC ITB
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to ITB / iShares U.S. Home Construction ETF on message board site Silicon Investor.
|FITBIT - tell us about your device||Andrew Breitbartu0027s Work Continues|
|FITB (Fifth Third Bancorp)||Hometown Auto (HCAR) - an internet/web play - profitbl co.|
|Pitbull Investing Strategies|
as of ET